Largest Dow Jones Biotechnology Companies By Total Asset

Total Asset
Total AssetEfficiencyMarket RiskExp Return
1ABBV AbbVie Inc
135.16 B
 0.20 
 1.38 
 0.27 
2AMGN Amgen Inc
91.84 B
 0.20 
 1.49 
 0.30 
3GILD Gilead Sciences
58.99 B
 0.22 
 1.55 
 0.34 
4REGN Regeneron Pharmaceuticals
37.76 B
(0.07)
 2.04 
(0.13)
5BIIB Biogen Inc
28.05 B
(0.07)
 1.73 
(0.12)
6VRTX Vertex Pharmaceuticals
22.53 B
 0.24 
 1.48 
 0.35 
7CRL Charles River Laboratories
7.53 B
(0.10)
 2.33 
(0.24)
8UTHR United Therapeutics
7.36 B
(0.10)
 2.28 
(0.22)
9BMRN Biomarin Pharmaceutical
6.99 B
 0.09 
 1.63 
 0.15 
10ILMN Illumina
6.3 B
(0.29)
 2.72 
(0.79)
11INCY Incyte
5.44 B
(0.08)
 2.18 
(0.17)
12ALNY Alnylam Pharmaceuticals
4.24 B
 0.08 
 3.00 
 0.25 
13NBIX Neurocrine Biosciences
3.72 B
(0.10)
 2.80 
(0.27)
14IONS Ionis Pharmaceuticals
B
(0.06)
 2.60 
(0.15)
15TECH Bio Techne Corp
2.7 B
(0.14)
 2.16 
(0.31)
16OPK Opko Health
2.2 B
 0.10 
 2.57 
 0.27 
17HALO Halozyme Therapeutics
2.06 B
 0.33 
 1.45 
 0.47 
18ALKS Alkermes Plc
2.06 B
 0.13 
 1.88 
 0.25 
19AGIO Agios Pharm
1.66 B
(0.04)
 2.55 
(0.11)
20NVAX Novavax
1.56 B
(0.02)
 4.65 
(0.10)
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value. Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.